Skip to main content
. 2023 Mar 22;10:1124743. doi: 10.3389/fmed.2023.1124743

Table 2.

Procedural characteristics and perioperative outcomes.

Group R (N = 131) Group P (N = 130) p-value NNT #/MD a.(95% CI)b
Primary outcome measure
Mild hypoxemia, no. (%) 37 (14.2) 30 (11.5) 0.396
Severe hypoxemia, no. (%) 11 (4.2) 24 (9.2) 0.019 10 (5 to 55)#
Adverse events
Bradycardia, no. (%) 10 (7.6) 12 (9.2) 0.642
Tachycardia, no. (%) 8 (6.1) 4 (3.1) 0.243
Hypotension, no. (%) 15 (11.5) 13(10) 0.705
Hypertension, no. (%) 4 (3.1) 1 (0.8) 0.178
Dizziness, no. (%) 8 (6.1) 9 (6.9) 0.789
Headache, no. (%) 1 (0.8) 2 (1.5) 0.622
PONVc, no. (%) 2 (1.5) 0 0.498
Hallucination, no. (%) 5 (3.8) 3 (2.3) 0.722
Chill, no. (%) 0 0
Other outcomes
Time to LoCd, s. (IQR) 53 (45 to 61) 50 (42 to 54) 0.001 4 (1 to 6)$
Duration of operation, min. (IQR) 16 (14 to 17.5) 15 (13 to 18) 0.083 1 (0 to 1)$
Time to recoverye, min. (IQR) 48 (41 to 58) 55.5 (46 to 67) <0.001 −8 (−11 to −4)$
Chin lift, no. (%) 25 (19.1) 40 (30.8) 0.029 9 (5 to 78)#
Mask ventilation, no. (%) 7 (5.3) 17 (13.1) 0.031 12 (7 to 127)#
Sedation rescuef, no. (%) 25 (19.1) 10 (7.7) 0.007 −9 (−31 to −5)#
Sedation failure, no. (%) 0 0
Accidental intubations, no. (%) 0 0
Use of Vasoactive drugs, no. (%) 9 (6.9) 11 (8.5) 0.629
Sedative drug total consumption g
Propofol, mg (IQR) 134 (120 to 157)
Remimazolam, mg (IQR) 13.5 (12 to 15)
Esketamine, mg (IQR) 38 (36.5 to 42) 39.5 (36.5 to 44) 0.227

Values are presented as number and percent (%) for categorical variables and mean (± SD) or median (Inter Quartile Range-IQR) as appropriate for continuous variables.

#

NNT (number needed to treat). Only given if both the upper and lower bounds of the NNT’s 95% confidence interval are positive or negative (to avoid confusing numbers that require treatment and numbers that require harm).

a

MD (median difference).

b

95% CI (95% confidence interval).

c

PONV (Postoperative nausea and vomiting).

d

Time to Loc (time to loss of consciousness), assessed by modified observer’s assessment alert/sedation scale.

e

Time to recovery, assessed by modified Aldrete scale, which monitoring from five dimensions: respiration, blood pressure, SpO2, activity, and consciousness, and the patients were allowed to leave the PACU when the modified Aldrete scale score ≥ 9.

f

refers to patients with up to three additional doses of remimazolam/propofol within the initial dose and 15 min.

g

The consumption of propofol and remimazolam was the total dosages required for induction and maintenance.